While Procept BioRobotics Corp has overperformed by 1.28%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRCT fell by -26.47%, with highs and lows ranging from $103.81 to $47.04, whereas the simple moving average fell by -15.64% in the last 200 days.
On July 09, 2025, Stephens started tracking Procept BioRobotics Corp (NASDAQ: PRCT) recommending Overweight. A report published by Oppenheimer on July 07, 2025, Initiated its previous ‘Perform’ rating for PRCT. Morgan Stanley also rated PRCT shares as ‘Overweight’, setting a target price of $105 on the company’s shares in an initiating report dated December 02, 2024. Jefferies Initiated an Hold rating on November 14, 2024, and assigned a price target of $95. Piper Sandler initiated its ‘Overweight’ rating for PRCT, as published in its report on August 11, 2023. BTIG Research also rated the stock as ‘Neutral’.
Analysis of Procept BioRobotics Corp (PRCT)
Further, the quarter-over-quarter increase in sales is 55.28%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Procept BioRobotics Corp’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -27.62% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.74, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 910.10K can be a very valuable indicator of volatility for PRCT stock. On a monthly basis, the volatility of the stock is set at 3.45%, whereas on a weekly basis, it is put at 2.94%, with a gain of 1.77% over the past seven days. Furthermore, long-term investors anticipate a median target price of $77.50, showing growth from the present price of $59.21, which can serve as yet another indication of whether PRCT is worth investing in or should be passed over.
How Do You Analyze Procept BioRobotics Corp Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.93%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 91.78% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
PRCT shares are owned by institutional investors to the tune of 91.78% at present.
